Eric Mate
Novartis (Australia)(AU)Teva Pharmaceuticals (Australia)(AU)
Research Areas
Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Health Systems, Economic Evaluations, Quality of Life, Autoimmune Bullous Skin Diseases
Most-Cited Works
- → Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study)(2022)11 cited
- → Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study(2022)7 cited